New Strategies Emerge In Competition For Federal Grants

You can’t take federal funding for granted anymore. That’s what an increasing number of scientists find out when they send proposals to the National Institutes of Health and the National Science Foundation, where the percentage of reviewed grants awarded has dropped considerably over the past 10 years. Latest NIH figures show that the agency’s award rate has dropped from more than 50% to just over 35% since 1979, while NSF has an award rate of slightly under 30%. Meanwhile

Written byJohn Lauerman
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

You can’t take federal funding for granted anymore. That’s what an increasing number of scientists find out when they send proposals to the National Institutes of Health and the National Science Foundation, where the percentage of reviewed grants awarded has dropped considerably over the past 10 years.

Latest NIH figures show that the agency’s award rate has dropped from more than 50% to just over 35% since 1979, while NSF has an award rate of slightly under 30%. Meanwhile, although appropriations have kept pace with inflation, the number of researchers applying for awards each year has increased by 18% at NSF and 14% at NIH since 1984.

Yet, many scientists prefer to. apply for federal funding rather than for grants from industry or private foundations, in part because federal sources tend to beef up their largess by tacking on as much as 33% the value of the grant for administrative ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies